SCLX Company Profile and Key Details

Q: Who are the executives of SCLX?

Dr. Suketu D. Desai Ph.D.Chief Technical Officer & Senior Vice President

NASDAQ : SCLX

Scilex

$8.50

0.69+8.83%

Open: 3:48 PM

58.15

ESG ScoreESG Rating

Profile Key Stats Analyst Ratings Ownership Ratios Financials Dividend & splits Sentiment Forecast

Price Chart

Stock Price Today

Scilex Holding Company (SCLX) stock surged +8.83%, trading at $8.50 on NASDAQ, up from the previous close of $7.81. The stock opened at $7.61, fluctuating between $7.03 and $8.85 in the recent session.

Stock Snapshot

7.81

Prev. Close

72.18M

Market Cap

7.03

Day Low

-0.22

P/E Ratio

-38.95

EPS (TTM)

-0.21

Cash Flow per Share

7.61

Open

8.49M

Number of Shares

8.85

Day High

78.54%

Free Float in %

-1.73

Book Value

2.24M

Volume

Relevant Articles

SEC Fillings

Current Report (8-k)

Filing Date	Accepted Date

Annual Report (10-k)

Filing Date	Accepted Date

Stock Price History Chart

Date	Open	High	Low	Close	Volume
Jul 02, 2026	7.93	8.49	7.69	7.81	60.23K
Jul 01, 2026	7.77	8.46	7.75	7.88	43.49K
Jun 30, 2026	7.75	7.90	7.46	7.80	57.36K
Jun 29, 2026	7.15	7.80	7.11	7.80	48.29K
Jun 26, 2026	7.00	7.48	6.92	7.11	34.64K
Jun 25, 2026	6.80	7.50	6.68	7.09	68.54K
Jun 24, 2026	6.80	7.08	6.60	6.86	30.8K
Jun 23, 2026	6.87	7.05	6.69	6.88	28.42K
Jun 22, 2026	7.22	7.32	6.79	6.87	71.4K
Jun 18, 2026	6.81	7.47	6.52	7.47	81.06K
Jun 17, 2026	5.71	7.14	5.53	6.94	181.67K
Jun 16, 2026	6.38	6.70	5.41	5.88	313.22K
Jun 15, 2026	8.48	8.59	7.91	7.95	65.16K
Jun 12, 2026	8.62	8.99	8.20	8.50	121.24K
Jun 11, 2026	8.30	9.23	7.92	8.70	91.4K
Jun 10, 2026	6.95	8.80	6.95	8.80	147.19K
Jun 09, 2026	7.00	7.20	6.82	7.04	29.86K
Jun 08, 2026	7.06	7.29	6.87	6.91	42.19K
Jun 05, 2026	7.76	7.76	6.82	7.00	39.18K
Jun 04, 2026	7.31	7.67	7.29	7.58	32.74K

Contact Details

Palo Alto, CA 94303

United States

https://www.scilexholding.com 650 516 4310

About Company

Scilex Holding Company is a biopharmaceutical enterprise that specializes in the development and market introduction of non-opioid therapies designed to alleviate both acute and chronic pain. Its primary marketed offering is ZTlido 1.8%, a topical prescription formulation of lidocaine specifically engineered to mitigate neuropathic discomfort associated with post-herpetic neuralgia, a condition characterized by persistent nerve pain following shingles. Beyond this, the company's development pipeline includes SP-102, a viscous gel corticosteroid for epidural administration, currently undergoing Phase III trials for lumbosacral radicular pain. Another candidate, SP-103, is progressing through Phase II trials for managing low back pain. Furthermore, SP-104, a novel, low-dose, delayed-release naltrexone hydrochloride formulation, has successfully concluded Phase I clinical testing for the treatment of fibromyalgia. Its corporate offices are situated in Palo Alto, California. Scilex Holding Company operates as a subsidiary of Sorrento Therapeutics, Inc.

Stock Peers

AMGN

12.82+3.55%

Amgen Inc.$374.15 BIIB

6.38+3.04%

Biogen Inc.$216.12 GILD

5.3+4.21%

Gilead Sciences, Inc.$131.27 HZNP

Horizon Therapeutics Public Limited Company$116.30 SNY

1.53+3.68%

Sanofi$43.16 GRFS

0.08+1.13%

Grifols, S.A.$7.16 MIRA

-0.0025-0.26%

MIRA Pharmaceuticals, Inc.$0.94 CTOR

-0.0239-3.39%

Citius Oncology, Inc.$0.68 SCLXW

0.02+12.50%

Scilex Holding Company$0.18

Company Overview

Scilex Holding Company (NASDAQ:SCLX) closed at $8.50 USD, gaining $0.69 (8.83%) from the previous close of $7.81. The stock is currently mid-range between its 52-week high and low $2.62 and $21.34. With a market capitalization of about $72.18 million, Scilex Holding Company is classified as a micro-cap and shows higher-than-market volatility (beta ~1.73). Key stats such as the average daily volume over the past year has been around 135.96 thousand shares, trading with heavier-than-usual volume. Headquartered in Palo Alto, CA, Scilex Holding Company operates in the Healthcare sector and the Drug Manufacturers - General industry. Led by CEO Henry H. Ji, the company employs approximately 115 people and listed since March 05, 2021. Scilex Holding Company is a biopharmaceutical enterprise that specializes in the development and market introduction of non-opioid therapies designed to alleviate both acute and chronic pain.

Technical Performance

SCLX has shown weak momentum, losing -18.73% over the past week and -14.79% over the past quarter, though year-to-date performance is down -10.74%. Short-term trend indicators are bullishly aligned (SMA20 -3.16%, SMA50 -26.09%, SMA200 -40.27%). The stock’s 14-day RSI is 36.49 (weak momentum), while the ATR of 0.78 points to higher daily volatility. The stock remains hovering near 52-week lows, trading -76.31% below its high and over 125.56% above its low. Average 10-day trading volume of 48.80 thousand shares is below the 3-month average of 90.97 thousand, indicating normal recent market interest.

Valuation Metrics

Scilex Holding Company trades at a P/E ratio of -0.2, slightly below the S&P 500 average, with a price-to-sales ratio of 1.96 and a price-to-book ratio of -0.22 indicating negative book value, which may reflect financial stress. The P/FCF stands at -10.06, also below market averages.

Dividend & Fair Value

Dividend and splits history remains an important factor for investors monitoring long-term returns.

Earnings & Analyst Outlook

Scilex Holding Company generated EPS of -$33.08 over the past year. Five-year average earnings growth is -526.67%. Scilex Holding Company earnings surprise history is a mixed track record. The quarter that ended May 20, 2026, missed forecasts by 1761.84%. The prior quarter beat by 878.72%. Over the last six quarters, Apple has recorded several small beats. These include -46.19% in May 14, 2025.

Shareholding & Insider Activity

Scilex Holding Company has 6.96 million shares outstanding. The public float is 2.92 million shares, elevated short interest at 10.80% of float. This equals 447.39 thousand shares. The short ratio is 2.05 days. Institutional investors hold 15.9% of the float. Insiders own 17.56%. Scilex Holding Co holds 244.45 million shares, Ji Henry has 2.60 million shares and Ma Stephen Hoi has 650.00 thousand shares. Over the past six months, insider transactions show net buying. They sold 650.00 thousand shares across 1 transactions.

Financial & Profitability Overview

Over the trailing twelve months, Scilex generated $46.74M in revenue, or $0.36 per share. Gross margin was 57.58%, operating margin -225.55%, and net profit margin -244.59%. Returns are negative, with ROA at -112.85% and ROE at 66.11%.
On valuation metrics, Scilex trades at a P/E of -0.20, P/S of 1.96 and P/B of -0.22. Liquidity is tight, with a current ratio of 0.08 and quick ratio of 0.07. Operationally, the company’s inventory turnover is 3.36 and cash conversion cycle is -2001.02 days , indicating it collects cash faster than it pays suppliers. Debt-to-equity is -0.43, supported by a cash flow-to-debt ratio of -0.03.

Quarterly Financial Highlights

For the quarter ended Dec 31, 2023, Scilex posted revenue of $46.74M, down slightly from $38.03M in the prior quarter. Gross profit was $26.92M (margin 57.58%). Operating income was - $105.43M (margin -225.6%). Net income was- $114.33M (EPS - $0.88).
The company ended the quarter with $3.92M in cash and short-term investments, a total debt of $128.46M, and net debt of $124.54M. Total assets were $101.31M, with equity of - $172.94M. Financials further reflected weakness, with operating cash flow of - $20.71M, free cash flow of - $21.04M, and capital expenditures of - $330.00K.

Price Forecast & Outlook

Our AI price prediction model suggests that Scilex Holding Company stock has strong potential for upside but may face short-term weakness followed by gains in the medium and long term. 2-Week Outlook: Projected increase of 6.02%, with price expected at $8.28 by July 16, 2026, within a range of $7.42 to $9.15 3-Month Outlook: Projected rise of 507.68%, reaching $47.46 by September 30, 2026, with a range of $45.84 to $49.21. 1-Year Outlook: Projected loss of -82.97%, with price at $1.33 by July 02, 2027, within a range of $0.00 to $0.00.

Key Takeaways

Scilex Holding Company (NASDAQ:SCLX) shares are down -10.74% year-to-date currently trading near 52-week highs band. Short-term momentum has been negative over the last quarter, despite recent volatility. Valuation shows Scilex Holding Company trading at a premium to the broader market with a P/E of -0.2. Analyst sentiment is bullish, with the majority of ratings in Buy territory and a mean price target of $13.33, suggesting 70.68% upside. Our AI forecast model points to short-term strength (6.02% over two weeks), a medium-term rise (507.68% over three months), and a longer-term loss (-82.97% over one year), with expected trading ranges indicating moderate volatility.

Frequently Asked Questions

What is the current Scilex Holding Company (SCLX) stock price?

Scilex Holding Company (NASDAQ: SCLX) stock price is $8.50 in the last trading session. During the trading session, SCLX stock reached the peak price of $8.85 while $7.03 was the lowest point it dropped to. The percentage change in SCLX stock occurred in the recent session was 8.83% while the dollar amount for the price change in SCLX stock was $0.69.

SCLX's industry and sector of operation?

The NASDAQ listed SCLX is part of Drug Manufacturers - General industry that operates in the broader Healthcare sector. Scilex Holding Company designs, manufactures, and markets smartphones, personal computers, tablets, wearables, and accessories worldwide.

Who are the executives of SCLX?

Dr. Suketu D. Desai Ph.D.
Chief Technical Officer & Senior Vice President

How SCLX did perform over past 52-week?

SCLX's closing price is 198.64% higher than its 52-week low of $2.62 where as its distance from 52-week high of $21.34 is -63.4%.

How many employees does SCLX have?

Number of SCLX employees currently stands at 115.

Link for SCLX official website?

Official Website of SCLX is: https://www.scilexholding.com

How do I contact SCLX?

SCLX could be contacted at phone 650 516 4310 and can also be accessed through its website. SCLX operates from 960 San Antonio Road, Palo Alto, CA 94303, United States.

How many shares of SCLX are traded daily?

SCLX stock volume for the day was 2.24M shares. The average number of SCLX shares traded daily for last 3 months was 135.96K.

What is the market cap of SCLX currently?

The market value of SCLX currently stands at $72.18M with its latest stock price at $8.50 and 8.49M of its shares outstanding.

Stocks Telegraph provides information and tools designed to assist investors and Wall Street players. A major goal is to offer financiers comprehensive information that will help them gain insight into investing.

Stocks Telegraph does not provide any advice or recommendations for buying or selling stocks, securities, or other financial products. Information contained on this website is for informational purposes only and should not be construed as professional financial, investment or other advice. Stocks Telegraph is not liable for any loss or damage that may occur as a result of reliance on this data.

Employees	115
Beta	1.73
Sales or Revenue	$46.74M
5Y Sales Change%	1.407%
Fiscal Year Ends	December
Sector	Healthcare
Industry	Drug Manufacturers - General

SCLX Company Profile and Key Details

Scilex

Price Chart

Stock Price Today

Stock Snapshot

Relevant Articles

SEC Fillings

Current Report (8-k)

Annual Report (10-k)

Stock Price History Chart

Contact Details

About Company

Company Information

Stock Peers

Company Overview

Technical Performance

Valuation Metrics

Dividend & Fair Value

Earnings & Analyst Outlook

Shareholding & Insider Activity

Financial & Profitability Overview

Quarterly Financial Highlights

Price Forecast & Outlook

Key Takeaways

Frequently Asked Questions

Shareholding & Insider Activity

Earnings & Analyst Outlook

Technical Performance

Financial & Profitability Overview

Quarterly Financial Highlights

Dividend & Fair Value

Company Overview

Valuation Metrics

Key Takeaways

Price Forecast & Outlook